Bayer Valuation
Is BAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BAY (PLN126.68) is trading below our estimate of fair value (PLN251.6)
Significantly Below Fair Value: BAY is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BAY?
Other financial metrics that can be useful for relative valuation.
| What is BAY's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €29.85b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 6.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BAY's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5x | ||
CLN Celon Pharma | 7x | 7.4% | zł1.5b |
UCB UCB | 5.6x | 10.8% | €30.7b |
4578 Otsuka Holdings | 2.1x | 1.0% | JP¥4.4t |
GALD Galderma Group | 5.4x | 11.5% | CHF 19.8b |
BAY Bayer | 0.6x | 1.3% | zł29.9b |
Price-To-Sales vs Peers: BAY is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (5.1x).
Price to Earnings Ratio vs Industry
How does BAY's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: BAY is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Pharmaceuticals industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is BAY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | 13.1x |
Price-To-Sales vs Fair Ratio: BAY is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (13.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | zł126.68 | zł146.32 +15.5% | 30.7% | zł290.60 | zł106.84 | n/a | 21 |
| Sep ’25 | zł119.68 | zł153.02 +27.9% | 34.1% | zł293.86 | zł108.04 | n/a | 22 |
| Aug ’25 | zł117.12 | zł153.54 +31.1% | 33.5% | zł291.49 | zł107.17 | n/a | 22 |
| Jul ’25 | zł113.60 | zł156.12 +37.4% | 32.9% | zł293.40 | zł107.87 | n/a | 22 |
| Jun ’25 | zł121.14 | zł156.74 +29.4% | 32.9% | zł290.92 | zł106.96 | n/a | 22 |
| May ’25 | zł120.22 | zł159.33 +32.5% | 33.3% | zł293.58 | zł107.94 | n/a | 21 |
| Apr ’25 | zł123.50 | zł161.52 +30.8% | 33.0% | zł292.12 | zł107.40 | n/a | 20 |
| Mar ’25 | zł120.56 | zł187.67 +55.7% | 30.0% | zł323.75 | zł107.92 | n/a | 21 |
| Feb ’25 | zł124.46 | zł207.25 +66.5% | 30.6% | zł373.92 | zł108.70 | n/a | 21 |
| Jan ’25 | zł148.56 | zł217.65 +46.5% | 28.5% | zł372.00 | zł108.14 | n/a | 22 |
| Dec ’24 | zł136.08 | zł236.30 +73.6% | 27.3% | zł388.92 | zł155.57 | n/a | 22 |
| Nov ’24 | zł182.92 | zł285.28 +56.0% | 18.3% | zł400.38 | zł191.29 | n/a | 22 |
| Oct ’24 | zł209.00 | zł303.42 +45.2% | 18.4% | zł414.42 | zł198.00 | zł126.68 | 21 |
| Sep ’24 | zł231.65 | zł298.10 +28.7% | 16.6% | zł402.15 | zł201.07 | zł119.68 | 21 |
| Aug ’24 | zł236.75 | zł304.05 +28.4% | 18.1% | zł429.80 | zł199.39 | zł117.12 | 21 |
| Jul ’24 | zł235.00 | zł326.76 +39.0% | 16.2% | zł434.18 | zł255.14 | zł113.60 | 20 |
| Jun ’24 | n/a | zł330.97 0% | 15.9% | zł440.70 | zł258.97 | zł121.14 | 21 |
| May ’24 | n/a | zł340.81 0% | 16.1% | zł458.63 | zł261.42 | zł120.22 | 22 |
| Apr ’24 | n/a | zł348.16 0% | 16.2% | zł467.66 | zł266.57 | zł123.50 | 22 |
| Mar ’24 | n/a | zł347.12 0% | 16.5% | zł462.53 | zł252.29 | zł120.56 | 23 |
| Feb ’24 | n/a | zł347.99 0% | 18.0% | zł498.52 | zł253.97 | zł124.46 | 23 |
| Jan ’24 | n/a | zł359.59 0% | 17.4% | zł497.12 | zł253.25 | zł148.56 | 22 |
| Dec ’23 | n/a | zł364.94 0% | 15.9% | zł495.99 | zł252.68 | zł136.08 | 22 |
| Nov ’23 | n/a | zł367.31 0% | 19.2% | zł502.95 | zł175.84 | zł182.92 | 22 |
| Oct ’23 | n/a | zł366.01 0% | 18.4% | zł504.97 | zł176.56 | zł209.00 | 23 |
Analyst Forecast: Target price is less than 20% higher than the current share price.